Immune Effects

Shikonin's immune story is smaller than its PKM2 story.

It is still worth attention because the mechanisms are specific rather than generic.

Immunogenic cell death

Shikonin can induce immunogenic cell death in breast-cancer models.

That matters because immunogenic cell death is not silent.

It releases danger signals and tumour antigens that can activate dendritic cells and support tumour-specific T-cell priming.

This is the basis for the dendritic-cell-vaccine work built around shikonin-treated tumour cells.

That work is early.

It still shows a real pathway, not just a theory.

Tumour-associated macrophage modulation

In ovarian-cancer models, shikonin reduces tumour-derived exosome production and limits exosomal GAL3-driven β-catenin activation.

The downstream effect is reduced M2-polarised macrophage support inside the tumour microenvironment.

That is important because M2 macrophages help tumours suppress immune surveillance and support invasion.

Necroptosis and inflammatory signalling

Necroptosis is inherently more inflammatory than classical apoptosis.

When shikonin pushes tumour cells into RIPK1/RIPK3-linked necroptosis, intracellular contents are released in a way that can amplify immune recognition.

That may be helpful in immune-cold tumours.

It may also raise off-target inflammatory questions.

The balance has not been resolved in humans.

Important limits

Several gaps still matter:

• no immune-competent human data

• no meaningful checkpoint-inhibitor combination literature

• most immunogenic-cell-death work comes from breast-cancer models

• microenvironment effects remain underexplored in intact animal immune systems

Bottom line

Shikonin has real immune relevance.

It is early, mechanistic, and still preclinical.

The strongest current angles are immunogenic cell death and macrophage-polarisation effects rather than broad immune enhancement claims.

Key references

Ahmad F et al. (2024). Shikonin in breast cancer treatment — ICD and immune findings. Journal of Pharmacy and Pharmacology.
https://academic.oup.com/jpp/article/76/8/967/7656703

Frontiers in Pharmacology (2025). Shikonin in female reproductive cancers — macrophage/exosome biology.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627124/full

Li Z et al. (2018). Necroptosis and RIPK1-RIPK3 axis — immunogenic cell death context. PMC.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6231221/